





60/236.368 29 September 2000 (29.09.2000) US  
 60/236.367 29 September 2000 (29.09.2000) US  
 60/237.039 2 October 2000 (02.10.2000) US  
 60/237.038 2 October 2000 (02.10.2000) US  
 60/237.040 2 October 2000 (02.10.2000) US  
 60/237.037 2 October 2000 (02.10.2000) US  
 60/236.802 2 October 2000 (02.10.2000) US  
 60/239.937 13 October 2000 (13.10.2000) US  
 60/239.935 13 October 2000 (13.10.2000) US  
 60/241.785 20 October 2000 (20.10.2000) US  
 60/241.809 20 October 2000 (20.10.2000) US  
 60/240.960 20 October 2000 (20.10.2000) US  
 60/241.787 20 October 2000 (20.10.2000) US  
 60/241.808 20 October 2000 (20.10.2000) US  
 60/241.221 20 October 2000 (20.10.2000) US  
 60/241.786 20 October 2000 (20.10.2000) US  
 60/241.826 20 October 2000 (20.10.2000) US  
 60/244.617 1 November 2000 (01.11.2000) US  
 60/246.474 8 November 2000 (08.11.2000) US  
 60/246.532 8 November 2000 (08.11.2000) US  
 60/246.476 8 November 2000 (08.11.2000) US  
 60/246.526 8 November 2000 (08.11.2000) US  
 60/246.527 8 November 2000 (08.11.2000) US  
 60/246.475 8 November 2000 (08.11.2000) US  
 60/246.525 8 November 2000 (08.11.2000) US  
 60/246.477 8 November 2000 (08.11.2000) US  
 60/246.528 8 November 2000 (08.11.2000) US  
 60/246.611 8 November 2000 (08.11.2000) US  
 60/246.610 8 November 2000 (08.11.2000) US  
 60/246.613 8 November 2000 (08.11.2000) US  
 60/246.609 8 November 2000 (08.11.2000) US  
 60/246.478 8 November 2000 (08.11.2000) US  
 60/246.524 8 November 2000 (08.11.2000) US  
 60/246.523 8 November 2000 (08.11.2000) US  
 60/249.299 17 November 2000 (17.11.2000) US  
 60/249.210 17 November 2000 (17.11.2000) US  
 60/249.216 17 November 2000 (17.11.2000) US  
 60/249.217 17 November 2000 (17.11.2000) US  
 60/249.211 17 November 2000 (17.11.2000) US  
 60/249.215 17 November 2000 (17.11.2000) US  
 60/249.218 17 November 2000 (17.11.2000) US  
 60/249.208 17 November 2000 (17.11.2000) US  
 60/249.213 17 November 2000 (17.11.2000) US  
 60/249.212 17 November 2000 (17.11.2000) US  
 60/249.207 17 November 2000 (17.11.2000) US  
 60/249.245 17 November 2000 (17.11.2000) US  
 60/249.244 17 November 2000 (17.11.2000) US  
 60/249.297 17 November 2000 (17.11.2000) US  
 60/249.214 17 November 2000 (17.11.2000) US  
 60/249.264 17 November 2000 (17.11.2000) US  
 60/249.209 17 November 2000 (17.11.2000) US  
 60/249.300 17 November 2000 (17.11.2000) US  
 60/249.265 17 November 2000 (17.11.2000) US  
 60/250.391 1 December 2000 (01.12.2000) US  
 60/250.160 1 December 2000 (01.12.2000) US  
 60/256.719 5 December 2000 (05.12.2000) US  
 60/251.030 5 December 2000 (05.12.2000) US  
 60/251.988 5 December 2000 (05.12.2000) US  
 60/251.479 6 December 2000 (06.12.2000) US

60/251.869 8 December 2000 (08.12.2000) US  
 60/251.856 8 December 2000 (08.12.2000) US  
 60/251.868 8 December 2000 (08.12.2000) US  
 60/251.990 8 December 2000 (08.12.2000) US  
 60/251.989 8 December 2000 (08.12.2000) US  
 60/254.097 11 December 2000 (11.12.2000) US  
 60/259.678 5 January 2001 (05.01.2001) US

**(71) Applicant (for all designated States except US): HUMAN GENOME SCIENCES, INC.** [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).

**(72) Inventors; and**

**(75) Inventors/Applicants (for US only): ROSEN, Craig, A.** [US/US]; 22400 Rolling Hill Lane, Laytonsville, MD 20882 (US). **BARASH, Steven, C.** [US/US]; 111 Watkins Pond Blvd., #301, Rockville, MD 20850 (US). **RUBEN, Steven, M.** [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US).

**(74) Agents: HOOVER, Kenley, K.** et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).

**(81) Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

**(84) Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

**(88) Date of publication of the international search report:**  
2 May 2002

**(15) Information about Correction:**

**Previous Correction:**

see PCT Gazette No. 36/2001 of 7 September 2001, Section II

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**INTERNATIONAL SEARCH REPORT**

international application No.

PCT/US01/01324

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
IPC(7) : C07H 21/02, 21/04; C12Q 1/68; C12P 21/06; C07K 2/00; A61K 30/00, 38/00		
US CL : 536/23.1, 24.1; 435/6, 7.1, 69.1, 320.1, 440; 530/300, 350; 424/184.1; 514/2, 44		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols) U.S. : 536/23.1, 24.1; 435/6, 7.1, 69.1, 320.1, 440; 530/300, 350; 424/184.1; 514/2, 44		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EAST, Derwent, Medline, GENBANK, (other DNA and protein databases)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database GENBANK on NCBI, Accession No. AB013478, HIROYAMA et al.	1, 2, 5, 7-10
---	Purification and characterization of a lysophosphatidic acid-specific phosphatase. 12	-----
Y	January 2000. Biochem J. 1998, Vol. 336, (Pt. 2), pages 483-489, see entire record. 87% identical to SEQ ID NO:11, 97% from nt61-nt643.	3, 4, 6, 17, 18, 22
X	Database GENBANK on NCBI, Accession No. AA088716, HILLIER et al. Generation and analysis of 280,000 human expressed sequence tags. 31 July 1997. Genome Res. 1996, Vol. 6, No. 9, pages 807-828, see entire record. 79% identical to SEQ ID NO:11, 97% from nt1-nt542.	1, 7-10
X	Database SWISSPROT on NCBI, Accession No. P4090, BARRELL et al. Direct	11
---	Submission. 01 November 1997. See entire record. 30% identical to SEQ ID NO:1274,	-----
Y	80% from aa21-aa31.	12-16, 19-21, 23-24
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents:		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier application or patent published on or after the international filing date	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"I"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed	
Date of the actual completion of the international search 20 July 2001 (20.07.2001)	Date of mailing of the international search report <b>02 AUG 2001</b>	
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230	Authorized officer <b>TERRY J. DEY</b> Mary K. Zeman PARALEGAL SPECIALIST TECHNOLOGY CENTER 1608 Telephone No. (703)308-6768	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/01324

**Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

- 1.  Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
- 2.  Claim Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
- 3.  Claim Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:  
Please See Continuation Sheet

- 1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
- 2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
- 3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
- 4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-24 in- part, SEQ ID NO:11 and 1274

- Remark on Protest**
- The additional search fees were accompanied by the applicant's protest.
  - No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

international application No.

PCT/US01/01324

### BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-24-in-part, drawn to inventions using SEQ: 11 (nucleic acid) and the encoded sequence SEQ ID NO: 1274 (polypeptides).

Group II, claim(s) 1-24-in-part, drawn to inventions using SEQ: 12 (nucleic acid) and the encoded polypeptide SEQ: 1275.

Group III, claim(s) 1-24-in-part, drawn to inventions using SEQ: 13 (nucleic acid) and the encoded polypeptide SEQ: 1276.

Group IV, claim(s) 1-24-in-part, drawn to inventions using SEQ: 14 (nucleic acid) and the encoded sequence SEQ ID NO: 1277 (polypeptides).

Group V, claim(s) 1-24-in-part, drawn to inventions using SEQ: 15 (nucleic acid) and the encoded polypeptide SEQ: 1278.

Group VI, claim(s) 1-24-in-part, drawn to inventions using SEQ: 16 (nucleic acid) and the encoded polypeptide SEQ: 1279.

Group VII, claim(s) 1-24-in-part, drawn to inventions using SEQ: 17 (nucleic acid) and the encoded sequence SEQ ID NO: 1280 (polypeptides).

Group VIII, claim(s) 1-24-in-part, drawn to inventions using SEQ: 18 (nucleic acid) and the encoded polypeptide SEQ: 1281.

Group IX, claim(s) 1-24-in-part, drawn to inventions using SEQ: 19 (nucleic acid) and the encoded polypeptide SEQ: 1282.

Groups X- Group 1248, claim(s) 1-24-in-part, drawn to each of SEQ: 20-1259, and each encoded polypeptide of 1283-2519.

The inventions listed as Groups 1-1248 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: each separate polynucleotide is a distinct invention, separable from all other polynucleotides. Each polynucleotide encodes differing polypeptides, having differing sequences and structures. Knowledge of one sequence does not shed light on any other sequence. The polynucleotides are not linked by any shared feature, structure or function. Therefore, the application lacks a shared special technical feature.